RALV
Technologies
IOL calculators
Service & handling
Sustainability
Congresses and events
Download Center
AddOn® trifocal
The AddOn trifocal is a sulcus lens for trifocal upgrades in pseudophakic eyes – available with +2.25 D or +3 D addition for near vision and, if required, a spherical refractive power of -5 D to +5 D.
1st INJECT Instrument
Single-use manual injector for the implantation of an AddOn IOL into the sulcus.
From 1.8 to 2.4 mm, depending on the cartridge size. Recommended for AddOn: 2.0 to 2.4 mm.
Cartridge + injector in blister; 1 disposable injection kit per box.
Silicone plunger for push injections.
3 years after sterilization.
Special click-lock system and guide rails for the easy placement of the lens.
Technical specifications
The upgrade for
pseudophakic eyes
The patented sulcus lens for optimized refraction results or subsequent upgrades for increased spectacle independence.
What users are saying
“I use the AddOn lens frequently in clinical practice to expand my options for refractive upgrades or corrections because of its dependable stability.”
“I feel very comfortable and safe with planned two-stage trifocality with a Basis IOL in the capsular bag and a trifocal AddOn in the sulcus. The superindication for this technique is RLE or post-LASIK cataract surgery. Refractive surprises should thus be entirely eliminated.”
“The AddOn can be used to bring pseudophakic patients back to their visual comfort zone at any time.”
“The AddOn with trifocal array is just great. In combination with the capsular bag lens it provides a high degree of adaptability to refractive situations. Handling and safety are convincing.”
“The main benefit of implanting a trifocal AddOn lens is the relative ease of reversibility at any given time […]. This is a smart option for patients who are particularly uncertain about how to handle aberrations from multifocal IOLs.”
Downloads
Individualized presbyopia correction
The innovative dual lens system enables increased spectacle independence and a unique degree of freedom.
Questions about the AddOn®
Yes, the AddOn is a sulcus lens that is implanted in addition to the capsular bag lens and is compatible with all commonly used IOLs, regardless of their design or material.
Thanks to their patented features(1), such as sulcus fit with 4 flexible haptics and rotational stability thanks to the non-torque design, the AddOn can be adapted to any sulcus size and shape.
(1) Patent #EP12181744
The AddOn lens can be implanted in the capsular bag any time after lens exchange. If a patient subsequently opts for increased spectacle independence, a trifocal AddOn is exactly the right solution.
The AddOn is placed in the sulcus and is therefore non-traumatically reversible at any time – even many years after the initial surgery.(1)(2)
(1) Khoramnia R, Baur ID, Yan W, Łabuz G, Auffarth GU Comparison of a Presbyopia-Correcting Supplementary Intraocular Lens Combination and a Capsular-Bag Lens: An In Vitro Study. Diagnostics 2023, 13, 1482. https://doi.org/10.3390/diagnostics13081482. (2) Gundersen KG, Gjerdrum B, Potvin R. Efficacy of a Secondary Trifocal Sulcus IOL in Providing Near and Intermediate Vision in Patients with Prior Myopic Laser Vision Correction and Cataract Surgery. Clinical Ophthalmology 2022;16:2219-2226.
No, the AddOn is only designed and patented for implantation in pseudophakic eyes.(1)
(1) Patent #EP12181744
Yes, the AddOn lens can be implanted together with the capsular bag lens in a single surgical intervention. When it comes to achieving spectacle independence for patients, the Liberty2 dual-lens system is worth considering.
Trifocality in the sulcus through elevated phase shift
1stQ uses innovative EPS technology. This means: optimized image quality, minimized glistening and outstanding trifocal performance.(1)
Find out more in our magazine
Literature and references
(1) Palomino-Bautista C, Sánchez-Jean R, Carmona Gonzales D, Romero Domínguez M, Castillo Gómez A. Spectacle independence for pseudophakic patients – Experience with a trifocal supplementary add-on intraocular lens. Clin Ophthalmol. 2020; 14:1043–1054.